loading page

The Interleukin 6 (IL-6) blockade for coronavirus disease 2019 (COVID-19) In Lung
  • +1
  • Zhili Rao,
  • Hongli Zhou,
  • Xiangyu Li,
  • Nan Zeng
Zhili Rao
Department of Pharmacology, College of Pharmacy, Chengdu University of Traditional Chinese Medicine,Chengdu city, Sichuan Province, Chengdu 611137, PR China
Author Profile
Hongli Zhou
National Drug Clinical Trial Institution, the Second Affiliated Hospital, Army Medical University, Chongqing 400037, China.
Author Profile
Xiangyu Li
Department of Pharmacology, College of Pharmacy, Chengdu University of Traditional Chinese Medicine,Chengdu city, Sichuan Province, Chengdu 611137, PR China
Author Profile
Nan Zeng
Chengdu University of Traditional Chinese Medicine

Corresponding Author:zengnan666@126.com

Author Profile

Abstract

COVID-19 has caused global pandemics since the emergent outbreak and resulted in a large number of deaths. IL-6, as an important autoimmune cytokine, had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients in COVID-19. A review of the relevant literature revealed more than one role for IL-6 in the lung infection because of its diverse biological effects. It may have a variety of different physiological functions in the development of lung infection. We have summarized its role in different progress of COVID-19, including lung infection, pneumonia, ALI, pulmonary fibrosis, and lung translation and even lung cancer. This will facilitate a deeper understanding of the role of IL-6 in the treatment of COVID-19.